Opinion
Video
Author(s):
Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.
Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
Braun Highlights Advances in RCC Treatment Paradigm, Looks Towards Future
Advancements With Combination Therapies in RCC Usher in New Questions
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC